Last week’s full-year results from GlaxoSmithKline (GSK) do not answer every concern the sceptics may have regarding current ...

Record FY2024 development sales of AED 33.6 billion, up 20% YoY driven by strong demand for new launches and existing ...

Neurocrine Biosciences exceeded earnings expectations for Q4 2024, driven by robust sales from key product Ingrezza, while ...

Trans Mountain Corporation is exploring options to increase the capacity of its pipeline by up to 300,000 barrels per day, ...

This is the conclusion of a recent analysis by commercial real estate investment firm Berkadia, which predicts Orlando will ...

Eli Lilly's innovative culture and strong financial commitment to developing the next generation of drugs set the company apart from its peers and fuel its long-term growth. Lilly holds ...

Refine unveils its state-of-the-art new HQ and Sales Gallery in the sky on 47th floor of Ubora Tower in Business Bay spanning ...

Of the 118 biologics losing exclusivity over the next decade, only 10% have biosimilars in development, meaning a vast ...

Amgen's Q4 earnings beat expectations, showcasing robust performance for the company's growth strategy. Click here to read ...

New-home construction has been pointed to as a bright spot in an otherwise difficult housing market, but the prospect of ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.JzBkOQ-g.js ...

GSK Plc plans to buy back £2 billion ($2.5 billion) of shares as it raised its long-term growth outlook on optimism around the drug pipeline.